EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Updated Phase 3 ARDS Results Continue to Show Mortality Benefit On February 24, 2026, Edesa Biotech, Inc. (NASDAQ:EDSA) announced additional Pha ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window HONOLULU -- As ...

A football club left without a grounds for a quarter of a century has scored a planning victory that could at last see it in a dream new home.

I would like your opinion on the role of corticosteroids in early and late ARDS. When should I institute steroids in my patient with ARDS? The complexities of the ARDSnet study and the variation seen ...

Inhaled sevoflurane significantly reduced ventilator-free days and 90-day survival versus IV propofol in moderate to severe ARDS. Inhaled volatile sedatives grew in popularity for prolonged use in ...

Inhaled sedation with sevoflurane in patients with moderate to severe acute respiratory distress syndrome (ARDS) resulted in fewer ventilator-free days at 28 days and lower 90-day survival than ...

Artificial ventilation can save lives, but it also puts pressure on lung tissue. If the lungs are pre-damaged, pressurized ventilation can even have undesirable effects. This is especially true of ...

Please provide your email address to receive an email when new articles are posted on . Pulmonary hypertension plus acute respiratory distress syndrome resulted in poor hospital outcomes. Odds for ...

In a recent study published in the journal Circulation, researchers investigate the inflammatory response to acute respiratory distress syndrome (ARDS) within the heart. Study: Virus-Induced Acute ...